285 related articles for article (PubMed ID: 27799738)
21. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab therapy for multiple sclerosis.
Coles AJ
Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
[TBL] [Abstract][Full Text] [Related]
23. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab: the advantages and challenges of a novel therapy in MS.
Menge T; Stüve O; Kieseier BC; Hartung HP
Neurology; 2014 Jul; 83(1):87-97. PubMed ID: 24920854
[TBL] [Abstract][Full Text] [Related]
25. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
26. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
[TBL] [Abstract][Full Text] [Related]
27. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
Jones DE; Goldman MD
Expert Rev Clin Immunol; 2014 Oct; 10(10):1281-91. PubMed ID: 25148422
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab and multiple sclerosis: therapeutic application.
Minagar A; Alexander JS; Sahraian MA; Zivadinov R
Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
[TBL] [Abstract][Full Text] [Related]
31. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
[TBL] [Abstract][Full Text] [Related]
33. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
34. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
[TBL] [Abstract][Full Text] [Related]
35. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
36. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
Costelloe L; Jones J; Coles A
Expert Rev Neurother; 2012 Mar; 12(3):335-41. PubMed ID: 22364332
[TBL] [Abstract][Full Text] [Related]
37. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
Ziemssen T; Engelmann U; Jahn S; Leptich A; Kern R; Hassoun L; Thomas K
BMC Neurol; 2016 Jul; 16():109. PubMed ID: 27430352
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
40. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
